000			01902cam a2200325 a 4500
003			EG-GiCUC
005			20250223031753.0
008			170812s2016 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aGift
097			_aPh.D
099			_aCai01.34.Ph.D.2016.Ya.D
100	0		_aYasmine Magdy Abbas Elfawal Mandour
245	1	0	_aDimeric adamantane analogs as inhibitors of viral M2 and p7 channels : _bSynthesis, molecular modeling and biological evaluation / _cYasmine Magdy Abbas Elfawal Mandour ; Supervised Darius P. Zlotos , Frank M. Boeckler , Hans G. Breitinger
260			_aCairo : _bYasmine Magdy Abbas Elfawal Mandour , _c2016
300			_a204 Leaves : _bcharts ; _c30cm
502			_aThesis (Ph.D.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceulical Chemistry
520			_aHCV represents a major health problem with about 170 million people infected worldwide. Among the difficulties in treating HCV is its high degree of genetic diversity with seven divergent genotypes identified each with many subtypes that respond differently to treatment. The HCV genome undergoes translation into eleven different structural and non-structural proteins. The non-structural proteins are responsible for viral replication and so represent important drug targets. However, direct-acting antivirals suffer from several setbacks and drugs targeting other HCV proteins may be useful for a more effective treatment
653		4	_aDimeric adamantane analogs
653		4	_aHCV
653		4	_aViral M2 and p7 channels
700	0		_aDarius P. Zlotos , _eSupervisor
700	0		_aFrank M. Boeckler , _eSupervisor
700	0		_aHans G. Breitinger , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c61899 _d61899